Radiotherapy for newly diagnosed oligometastatic prostate cancer by L. Boeri et al.
Comment
www.thelancet.com   Vol 392   December 1, 2018 2327
Radiotherapy for newly diagnosed oligometastatic prostate 
cancer
The standard of care for metastatic prostate cancer is 
systemic therapy in the form of androgen deprivation 
therapy with or without novel antiandrogens or 
chemotherapy.1 Administering local treatment to the 
primary tumour in the setting of metastatic prostate 
cancer has long been postulated to have a survival 
benefit on the basis of retrospective series.2–7 But 
such series can have selection bias in that patients 
undergoing local treatment can also have a low volume 
of metastatic disease (oligometastases), creating a 
major confounder in most analyses. To date randomised 
controlled trials investigating this subject have been 
sparse, and the value of local control in metastatic 
prostate cancer has been debated.
In The Lancet, Christopher Parker and colleagues8 
present results of the STAMPEDE randomised controlled 
trial comparing standard of care (androgen deprivation 
therapy with or without docetaxel) with external-beam 
radiotherapy to the prostate. 2061 men with newly 
diagnosed metastatic prostate cancer who had received 
no previous treatment to the primary tumour were 
enrolled from 117 hospitals in Switzerland and the UK. 
Radiotherapy improved failure-free survival compared 
with standard of care alone (hazard ratio [HR] 0·76, 
95% CI 0·68–0·84; p<0·0001), but overall survival was 
not improved (0·92, 0·80–1·06; p=0·266). However, 
in a prespecified analysis, men were stratified using 
the CHAARTED9 definition for low or high metastatic 
burden. In patients with a low metastatic burden 
(n=819), radiotherapy improved 3-year overall survival 
compared with standard of care (81% vs 73%; HR 0·68, 
95% CI 0·52–0·90; p=0·007), and failure free survival 
was also improved (0·59, 0·49–0·72; p<0·0001). 
Patients with a high metastatic burden did not benefit 
from radiotherapy in terms of failure-free survival 
or overall survival. Parker and colleagues concluded 
that radiotherapy should be an option for men with 
newly diagnosed metastatic prostate cancer and a low 
metastatic burden.8
A relevant trial in this area of research is the HORRAD 
study.10 432 men with metastatic prostate cancer were 
randomly allocated androgen deprivation therapy 
either alone or with radiotherapy. No difference in 
overall survival was noted between the two treatment 
groups, but in the subgroup of men with low vol ume 
of metastatic disease (n=160), radiotherapy showed 
some improvement in overall survival (HR 0·68, 95% CI 
0·42–1·10), although the finding was not significant. The 
similar effect size for radiotherapy in men with low 
metastatic burden in the HORRAD and STAMPEDE trials, 
but the absence of statistical significance in HORRAD, 
suggests that HORRAD was underpowered from the 
standpoint of metastatic burden. We estimate that more 
than 250 men would have needed to be randomised to 
have an 80% probability of detecting a difference with 
an HR of 0·75. Taken together, both these trials build the 
case for local radiotherapy in selected men with newly 
diagnosed oligometastatic prostate cancer.
As with any trial, STAMPEDE does have several 
limitations. First, the main finding of improved survival 
with radiotherapy in the cohort with a low metastatic 
burden is based on a subgroup analysis and should 
be interpreted cautiously. Next, the analysis did not 
test various definitions of oligometastatic prostate 
cancer, leaving open the possibility for patients with 
(for instance) five bone metastases to potentially 
benefit from local therapy. Defining a metastatic 
volume threshold above which patients are unlikely 
to benefit from local therapy is an important area of 
further study. Also, metastatic deposits in STAMPEDE 
were identified using conventional imaging, and 
such a trial might hold less weight as more sensitive 
PET imaging becomes commonplace. The trial also 
did not comment on patients with non-regional (eg, 
retroperitoneal or thoracic or other) lymph-node-only 
metastases, a relatively common scenario. Do they 
benefit more from cytoreductive radiotherapy than the 
average oligometastatic patient with bone metastases? 
Moreover, the incidence of symptomatic local events 
was similar between control and radiotherapy groups, 
suggesting that radiotherapy might not add much local 
control benefit beyond androgen deprivation therapy 
with the dosage used in STAMPEDE—a counterintuitive 
finding. Furthermore, the total dose of radiation 
delivered in STAMPEDE (either 36 Gy in six fractions or 
55 Gy in 20 fractions) was significantly lower than the 
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Functional mutation analyses in patients with immune 
deficiencies identified Janus kinases (JAKs) as plausible 
regulators of the immune response. Thereafter, elegant 
signalling biology generated a compelling rationale for 
the use of small molecule inhibitors to recapitulate the 
cytokine blocking activities of biologics. JAK inhibitors 
have thus emerged as novel immune modifiers that 
target cytokines via blockade of intracellular cytokine 
receptor signalling pathways. Four members of the 
family (JAK1, JAK2, JAK3, and TYK2) can form a variety 
of heterodimers (eg, JAK1/JAK2 and JAK1/JAK3) and 
transmit signals from the cell membrane to the nucleus 
(via cytosolic shuttling proteins) to activate leucocytes 
and stromal cells and drive inflammation.1 In the past 5 
years, JAK inhibitors were developed for the treatment 
of rheumatoid arthritis;1 now attention has turned to 
their wider use across immune-mediated inflammatory 
diseases.
Spondyloarthritis comprises a group of clinically 
and pathogenetically related immune-mediated in-
flammatory diseases, including psoriatic arthritis 
and axial spondyloarthritis. These conditions impair 
quality of life and, by virtue of accelerated comorbidity, 
reduce life expectancy.2,3 Although novel biological 
therapies, including inhibitors of tumour necrosis 
factor (TNF), interleukin (IL)-12/IL-23 p40, IL-17A, 
and IL-23 p19, have transformed the management of 
psoriatic arthritis,2,4,5 and TNF and IL-17A inhibitors the 
management of axial spondyloarthritis,6 unmet need 
remains for these lifelong, incurable conditions. Patients 
with psoriatic arthritis with articular and entheseal 
disease often only partly respond or do not respond at 
all to treatment, with few patients reaching sustained 
minimal disease activity. Moreover, pain control is 
suboptimal, and therapeutic tapering and drug-free 
remission remain challenging and rarely achieved 
goals. Orally bioavailable therapeutics are intriguing 
in this context. A phosphodiesterase type 4 inhibitor, 
apremilast, is approved for use in patients with psoriatic 
arthritis. More recently, tofacitinib (an inhibitor of JAK1/
JAK3) showed efficacy in patients with psoriatic arthritis 
and ankylosing spondylitis, offering the first clue that 
JAK family inhibition might offer general benefits to 
patients with spondyloarthritis.7, 8
The extending scope of kinase inhibition in immune diseases
70 Gy or greater given for high-risk localised prostate 
cancer.11 Thus, dose-optimisation studies are needed to 
reach a balance between local and oncological control 
and quality of life in the metastatic setting.
Based on the findings of STAMPEDE,8 radiotherapy 
could be considered for patients with newly diagnosed 
oligometastatic prostate cancer, but further studies 
are needed to delineate the clinical implementation of 
such treatment.
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